An observational study in Eye Disease, sponsored by University of Colorado, Denver. Terminated at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-17.
Sponsored by University of Colorado, Denver · Observational
The significance of our study is in the importance of understanding the quality and quantity of proteins in the human tear film from diseased and non-diseased patients. This pilot study will provide data to plan prospective research to better delineate the utility of tear proteins in diagnosing and following disease status in a non-invasive fashion.
740 studies on the registry are indexed under Eye Diseases; 117 are open to participants now.
This study's enrollment of 63 is below the median of 120 across 172 observational studies indexed under Eye Diseases.
Browse Eye Diseases studies →University of Colorado, Denver is the lead sponsor of 1,499 studies on the registry; 315 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 89 (64%) have results posted.
Counted across the registry records on this site, refreshed daily.
Subjects receiving eye examination
Exclusion Criteria:
Subjects receiving eye examination
Other: Eye Examination
Subjects receiving eye examination
Plan Prospective Research
Pilot study will provide data to plan prospective research to better delineate the utility of tear proteins in diagnosing and following disease status in a non-invasive fashion.
Time frame: Throughout study participation
This study is terminated, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver